国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語Fran?ais
Opinion
Home / Opinion / Featured Contributors

Chinese vaccine a shot of equity for world

By Seymur Mammadov | chinadaily.com.cn | Updated: 2021-01-25 17:01
Share
Share - WeChat
A medical worker displays China's Sinovac COVID-19 vaccine before the vaccination at a hospital in Baku, Azerbaijan, Jan 18, 2021. [Photo/Xinhua]

COVID-19 vaccinations have begun in countries around the world, and Azerbaijan is among them. Officials including Azerbaijani Health Minister Ogtay Shiraliyev and Deputy Health Minister Elsavar Agayev have already received the vaccine.

What's interesting here is the fact that Azerbaijan chose to use the vaccine from the Chinese company Sinovac. The vaccine has been clinically tested in several countries and has shown good results without complications.

In addition, it has been proven that while re-infection after Sinovac is possible, the illness would be very easily tolerated. Considering all these advantages, Baku chose the Chinese vaccine.

Earlier, the option of purchasing the Russian vaccine Sputnik-V was discussed, but Sinovac was selected instead.

Azerbaijan decided to entrust the health of its citizens to China after Turkey. Last week, Turkish President Recep Tayyip Erdogan was vaccinated against the coronavirus - he received the first dose of CoronaVac from the Chinese company Sinovac. The Turkish Minister of Health was vaccinated even earlier. Overall, the country has already ordered 50 million doses from China.

Brazil, the UAE, Ukraine, Indonesia, Mexico and other countries were among the first to acquire the Chinese vaccine.

The issue of the availability of vaccines against coronavirus is no less pressing today than the pandemic itself. This is indeed a very serious problem, because many countries around the world do not have access to life-saving vaccines due to the high cost.

Western countries have created a kind of club in which only wealthy buyers are allowed. The Pfizer and BioNTech vaccines are approved in the US, although the American drug Pfizer has not received particularly good reviews. If you flip through the news, you can see dozens of reports of complications or even deaths after taking this vaccine.

Meanwhile, China has been dedicated to making its vaccine available to more people. "We will fulfill our obligations and make the coronavirus vaccines available to the whole world," Chinese President Xi Jinping said earlier at the G20 summit. Today, Beijing is already actively meeting its commitments, and the Chinese vaccine is expected to help solve the coronavirus problem in many countries around the world. Indonesian President Joko Widodo called the Chinese vaccine "great news for our people."

China has joined the COVAX international initiative to promote the equitable distribution of vaccines around the world. I must say that about 190 countries have joined the initiative, but none of them is working as actively as China. Predictably, provocative rumors began to spread from the West to discredit the Chinese drug. Publications by some specialists began to appear in an effort to question the effectiveness and safety of the Sinovac vaccine.

And in connection with the purchase of a Chinese drug by Indonesia, Beijing was accused of using the coronavirus vaccine as a tool to influence geopolitics. With this, some large countries revealed their own intentions, since the West itself put the issue of a vaccine against COVID-19 on political rails from the very beginning.

Meanwhile, China, as a responsible member of the UN and WHO, has repeatedly stated that it is ready to work closely with all parties, prioritizing the needs of developing countries and promoting fair, equitable and rational distribution of vaccines around the world. It is precisely the equality in this issue that, apparently, does not suit the West.

In short, a vaccine war is unfolding in the world. China offers an affordable vaccine that everyone can use. The Chinese drug is used in Asia, Latin America, the Middle East, North Africa and post-Soviet areas - that is, practically all over the world. Competitors and envious people do not wish Beijing to succeed on this path. But China is no stranger to it. It will break through.

The author is director of the international experts' club EurAsiaAz, and editor-in-chief of Azerbaijan's news agency, Vzglyad.az.

The opinions expressed here are those of the writer and do not necessarily represent the views of China Daily and China Daily website.

Most Viewed in 24 Hours
Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
太仓市| 沙坪坝区| 盖州市| 安远县| 青岛市| 漳州市| 长兴县| 文安县| 宁晋县| 会理县| 汉源县| 清流县| 双辽市| 日喀则市| 白朗县| 江永县| 普陀区| 台中县| 勐海县| 铜陵市| 花莲市| 石城县| 抚宁县| 孟州市| 景宁| 永顺县| 土默特右旗| 黑山县| 南川市| 西丰县| 安顺市| 故城县| 宜章县| 玉门市| 厦门市| 砚山县| 赤峰市| 博兴县| 和静县| 方山县| 中牟县|